Gene Therapy Protocol Linked To Death Was Altered At FDA - RAC's Walters
Executive Summary
The gene therapy protocol implicated in the September death of an Arizona patient was modified during FDA review after the study was approved by the NIH Recombinant DNA Advisory Committee, panel members who evaulated the trial assert.
You may also be interested in...
NIH-FDA Gene Therapy Trial Adverse Event Reporting Study Under Way
NIH and FDA will conduct a comparative analysis of "the number of serious adverse events in human gene therapy trials reported to each agency," outgoing NIH Director Harold Varmus, MD, said in a Dec. 1 letter to Senate Health/Public Health Subcommittee Chair Frist (R-Tenn.).
NIH-FDA Gene Therapy Trial Adverse Event Reporting Study Under Way
NIH and FDA will conduct a comparative analysis of "the number of serious adverse events in human gene therapy trials reported to each agency," outgoing NIH Director Harold Varmus, MD, said in a Dec. 1 letter to Senate Health/Public Health Subcommittee Chair Frist (R-Tenn.).
FDA, NIH Gene Therapy Oversight Roles To Be Questioned By Rep. Waxman
Rep. Waxman (D-Calif.) plans to ask FDA how the agency balances the proprietary rights of sponsors with the expectation of greater public scrutiny of gene therapy trials.